Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim of a ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...